Pacific Biosciences Stock Rises Above 200-Day Average

Shares of the genetic sequencing company reach a new high after passing a key technical milestone.

Published on Feb. 1, 2026

Got story updates? Submit your updates here. ›

Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) rose above their 200-day moving average on Friday, trading as high as $2.36 before closing at $2.26. The stock saw heavy trading volume of over 8.5 million shares. The move comes as analysts have increased their price targets for the company, citing improved financial performance and growth prospects.

Why it matters

Passing the 200-day moving average is seen by many investors as a bullish technical signal, indicating the stock may be entering a new upward trend. This could attract additional buying interest and further boost the share price. Pacific Biosciences is a leading provider of genetic sequencing technology, an industry that is expected to see strong growth in the coming years as demand for genomic analysis continues to rise.

The details

Pacific Biosciences' stock has been on the rise in recent months, with several analysts upgrading their price targets. Stephens increased its target from $1.80 to $2.00 and maintained an 'overweight' rating, while Piper Sandler raised its target from $1.50 to $2.00 and kept a 'neutral' rating. Barclays also increased its price objective from $1.50 to $2.00, though it maintained an 'equal weight' rating on the stock.

  • Pacific Biosciences' stock price passed above its 200-day moving average of $1.74 during trading on Friday, February 1, 2026.

The players

Pacific Biosciences of California, Inc.

A leading provider of genetic sequencing technology, developing and selling high-performance DNA sequencing systems for genetic and genomic analysis.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Pacific Biosciences' stock passing above its 200-day moving average is a positive technical signal that could attract more investor interest and further boost the share price. As a leader in the growing genetic sequencing industry, the company's improved financial performance and growth prospects make it an increasingly attractive investment option.